Explain pharmacogenomics — Hinglish notes

6.1.11 · Biology › Genomics

Pharmacogenomics Kya Hai?

Key distinction:

Pharmacogenetics = single-gene effects on drug response
Pharmacogenomics = genome-wide analysis (multiple genes + pathways)

Genetics Drug Response Ko Kaise Affect Karta Hai: Teen Pillars

1. Pharmacokinetics: "Body Drug Ko Kya Karta Hai"

Formula ADME Framework

Drug ka body mein safar: $Drug Dose Absorption Blood Distribution Tissues Metabolism Metabolites Excretion Out$

Genetic variations har step ko affect karte hain:

Absorption: Intestinal transporters (e.g., P-glycoprotein/MDR1 gut wall mein) uptake control karte hain

Poor uptake → drug gut mein reh jaata hai → blood mein low levels

Distribution & Hepatic Uptake: SLCO1B1 (OATP1B1) ek hepatic uptake transporter hai jo statins ko blood se liver ke andar le jaata hai; P-glycoprotein drugs ko cells se bahar pump karta hai (e.g., brain)

SLCO1B1 variants → statins blood/muscle mein reh jaate hain → toxicity

Metabolism: Liver mein Cytochrome P450 (CYP) enzymes $Active Drug CYP2D6, CYP2C19, etc. Inactive Metabolite$

CYP2D6 poor metabolizers (~7% Europeans): Codeine ko morphine mein convert nahi kar sakte → koi pain relief nahi
CYP2D6 ultra-rapid metabolizers (~29% East Africans): Codeine → excess morphine → toxicity risk

Excretion: Kidney transporters metabolites clear karte hain

Variants → drug build up ho jaata hai → prolonged action

Yeh kyun matter karta hai: "Normal" codeine dose zyaadatar logo ke liye safe hai lekin ultra-rapid metabolizers ke liye dangerous hai — yeh bahut zyaada morphine bahut jaldi produce karte hain (iss genotype wali breastfeeding mothers se infants ki jaan gayi hai).

2. Pharmacodynamics: "Drug Body Ko Kya Karta Hai"

Drug targets (receptors, enzymes) bhi vary karte hain:

3. Immune-Mediated Reactions

Kuch alleles severe hypersensitivity predict karte hain:

CYP450 System: Deep Dive

Clinical Implementation

Worked example Real-World Protocol

Scenario: Cholesterol ke liye nayi statin prescription.

SLCO1B1 genotype karo (hepatic uptake transporter gene)

c.521T>C variant → liver mein OATP1B1 uptake reduced (CC homozygotes mein normal efficiency ka ~40%)

Statin levels predict karo (uptake efficiency se inverse proportionality): $AUC_{variant} = \frac{AUC _{normal}}{0.4} = 2.5 \times AUC_{normal}$ Kam liver uptake → zyaada statin blood mein reh jaata hai → higher exposure.
Risk assess karo: Published data CC vs TT genotype mein myopathy ke liye odds ratio ≈ 4.5 deta hai (yeh ek odds ratio hai, na ki literal 4.5× absolute risk — myopathy absolute terms mein rare rehti hai)
Adjust karo: Alternative statin use karo (pravastatin/rosuvastatin, less SLCO1B1-dependent) ya simvastatin dose kam karo

Outcome: Rhabdomyolysis (muscle breakdown → kidney failure) prevent karo.

Pharmacogenomics Mein Common Mistakes

Active Recall Questions

#flashcards/biology

Pharmacogenomics kya hai?

Yeh study hai ki genetic variations individual drug responses (efficacy aur toxicity) ko kaise influence karti hain, pharmacology aur genomics combine karke personalized medicine enable karta hai.

Chaar ADME processes kya hain aur genetics unhe kaise affect karta hai?

Absorption (intestinal transporter variants uptake change karte hain), Distribution/hepatic uptake (SLCO1B1/OATP1B1 statins ko liver mein move karta hai; P-glycoprotein tissue levels affect karta hai), Metabolism (CYP450 polymorphisms clearance alter karte hain), Excretion (renal transporter variants elimination change karte hain).

SLCO1B1 (OATP1B1) actually kya karta hai, aur iska variant statin myopathy risk kyun badhata hai?

Yeh ek HEPATIC UPTAKE transporter hai jo statins ko blood se liver cells MEIN move karta hai (gut absorption transporter nahi hai). Loss-of-function variant (c.521T>C) → kam liver uptake → blood/muscle mein zyaada statin exposure → myopathy risk badh jaata hai (CC vs TT ke liye odds ratio ~4.5).

CYP2D6 ultra-rapid metabolizers codeine par kaise respond karte hain?

Woh codeine ko morphine mein jaldi convert karte hain, ZYAADA, tezi se morphine levels produce karte hain — aksar enhanced analgesia hoti hai lekin serious toxicity risk (respiratory depression) bhi hoti hai. Sirf codeine→morphine conversion accelerate hoti hai; morphine ki apni clearance unchanged rehti hai.

CYP2D6 POOR metabolizers codeine par kaise respond karte hain?

Woh codeine ko morphine mein convert nahi kar sakte, isliye normal doses par bhi unhe bahut kam ya koi analgesia nahi milti.

Derive karo ki VKORC1 variant warfarin dosing ko kaise affect karta hai

Dose_variant = Dose_normal × (IC50_variant / IC50_normal). Agar variant enzyme zyaada sensitive hai (IC50 half ho gayi), toh same inhibition achieve karne ke liye dose half kar do. CYP2C9 poor metabolizer add karo → slower clearance → aur kam karo.

HLA-B*5701 kya hai aur iske liye test kyun karein?

Yeh ek MHC class I allele hai jo abacavir-peptide complexes ko T cells ke saamne present karta hai, hypersensitivity trigger karta hai (fever, rash, organ damage). Abacavir se pehle testing life-threatening reactions rokti hai (~8% → <1%).

CYP2D6 poor metabolizers mein tramadol kyun fail karta hai explain karo

Tramadol ek inactive prodrug hai jise O-desmethyltramadol (bahut zyaada potent) banane ke liye CYP2D6 chahiye. Poor metabolizers mein yeh conversion nahi hoti → koi analgesia nahi; dose badhane se parent compound se seizures aate hain.

Pharmacogenomics mein odds ratio vs absolute risk?

Ek odds ratio (e.g., SLCO1B1 CC ke liye ~4.5) odds compare karta hai, absolute event rates nahi. Rare baseline (myopathy) ke saath, bada OR bhi absolute risk low rakhta hai — OR ko kabhi literal fold-increase in personal risk mat maano.

Recall Ek 12-Saal Ke Bachche Ko Explain Karo

Socho medicine ek key ki tarah hai jo tumhare body ke lock mein fit honi chahiye. Lekin sabka lock thoda alag hota hai apne DNA ki wajah se!

Kuch logon ke paas "fast locks" hote hain jo kuch medicines ko unki active form mein super jaldi turn kar dete hain. Codeine ke liye, "fast" logon mein bahut saara strong stuff (morphine) bahut jaldi banta hai — jo actually bahut zyaada ho sakta hai aur dangerous hota hai. "Slow" log key ko bilkul turn nahi kar paate, toh codeine unke dard ke liye kuch nahi karta.

Doosri medicines, jaise cholesterol ke liye statins, ko SLCO1B1 naam ke ek chhote darwaze se liver ke andar kheecha jaana chahiye. Agar tumhara darwaza chhota hai (ek gene variant), toh medicine tumhare blood mein float karti rehti hai aur tumhari muscles ko nuksan pahuncha sakti hai. Toh scientists pehle tumhara DNA padhte hain sahi medicine aur sahi dose choose karne ke liye. Yeh tumhare apne body ka cheat code hai!

Connections

6.1.1-Human-genome-structure – Genetic variation (SNPs, CNVs) allele diversity banate hain
6.1.8-Genome-wide-association-studies – GWAS drug-response variants identify karta hai
5.2.3-Enzyme-kinetics – Michaelis-Menten drug metabolism par apply hota hai
7.3.5-Cancer-pharmacology – Tumor genetics chemotherapy response predict karte hain (e.g., EGFR mutations → gefitinib)
3.4.2-Liver-metabolism – Hepatic phase I/II reactions, CYP450 aur OATP1B1 localization
4.5.1-Immune-recognition – HLA system aur hypersensitivity mechanisms
2.1.6-Membrane-transporters – Drug handling mein ABC (P-gp) aur SLC (OATP1B1) families

Clinical note: As of 2026, FDA labels include pharmacogenomic information for 400+ drugs. CPIC guidelines provide dosing recommendations. Direct-to-consumer tests exist but require physician interpretation.